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Abstract 
Artichoke (Cynara scolymus L.) is full of natural antioxidants and has a 
lipid-lowering effect.  The aim of this study was to investigate the effect of 
artichoke on the liver phosphatidate phosphohydrolase, plasma lipid 
levels, plasma malondialdehyde, and plasma antioxidant in rats fed by 
lipogenic diet. Male rats were fed by standard pellet diet (group I), 
standard diet supplemented with 10% artichoke (group II), lipogenic diet 
(containing sunflower oil, cholesterol and ethanol) plus 10% artichoke 
(group III) and only lipogenic diet (group IV). On day 60 of the 
experiment, liver phosphatidate phosphohydrolase activity, liver 
triglyceride, plasma lipids, plasma malondialdehyde, and plasma 
antioxidant levels were measured. Phosphatidate phosphohydrolase 
activity, liver triglyceride, the ratio of total cholesterol to high density 
lipoprotein cholesterol, plasma total cholesterol and triglyceride levels 
were significantly decreased due to artichoke treatment in groups II and III 
compared to groups I and IV, respectively. Significant reduction in plasma 
malondialdehyde and significant elevation in plasma antioxidant power 
observed in groups II and III compared to groups I and IV, respectively. 
The results clearly indicated that artichoke can be useful for the reduction 
of phosphatidate phosphohydrolase activity and liver triglyceride. Also, 
artichoke has beneficial effects in the controlling of hyperlipidemia, 
abnormalities in lipid profiles and oxidative stress in hyperlipidemic 
regimes.  
Keywords: artichoke, hypercholesterolemia, liver triglyceride, plasma 
lipids, phosphatidate phosphohydrolase.  
Introduction 
Alterations in serum lipid and lipoprotein levels, 
especially hypercholesterolemia, result in a 
variety of chronic diseases such as coronary heart 
diseases and atherosclerosis [1-3]. Many studies 
have been conducted on plant flavonoids that 
might be beneficial in reducing the risk of obesity 
and its complications [4, 5]. In this respect, 
artichoke (Cynara scolymus L.) is introduced as 
new lipid-lowering therapeutic agent [6, 7]. 
Artichoke leaves were used in traditional 
medicine for a variety of diseases especially,  
 
hyperlipidemia. Hypolipidemic effects of 
artichoke have been documented in experimental 
and clinical studies [7, 8]. Also, artichoke is full 
of natural bioactive components, i.e., caffeic acid, 
chlorogenic acid, cynarin, and luteolin. These 
components reduce the production of reactive 
oxygen species (ROS), lipid peroxidation and the 
oxidation of low-density lipoproteins in vitro 
experiments [9-11]. Therefore, these properties of 
artichoke warrant its application in traditional 
medicine. 
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Phosphatidate phosphohydrolase (PAP, EC 
3.1.3.4) catalyzes the dephosphorylation of 
phosphatidic acid to yield inorganic phosphate 
(Pi) and 1 ,2 diacylglycerol. This enzyme is a 
regulatory step in controlling the synthesis of 
glycerophospholipids and triacylglycerols [12].  
The produced diacylglycerol serves as a 
precursor for the biosynthesis of major 
glycerolipids in animal cells [12, 13]. In addition, 
triglyceride (TG) serves as an important storage 
molecule that allows organism to survive periods 
of food deprivation. In human diseases, the 
regulation of TG storage is very important 
because both excessive and inadequate fat storage 
are accompanied with dyslipidemia, insulin 
resistance, and diabetes [14, 15]. In rat liver, two 
distinct forms of PAP have been reported based 
on N-ethylmaleimide (NEM) sensitivity [12, 16]. 
The NEM-sensitive form (PAP1), located in 
cytosol and microsomal fraction, requires Mg2+ 
for its activity and is a regulatory enzyme in TG 
and phospholipids biosynthesis [12]. The second 
form is PAP2. It presents in plasma membrane 
and does not require Mg2+ for its activity. This 
form is primarily involved in lipid signaling 
pathways by modulating the second messengers 
of diacylglycerol and phosphatidic acid [17, 18].  
Most of the previous studies on artichoke have 
shown that artichoke has cholesterol and 
triglyceride-lowering effects [7, 8]. A study has 
shown the inhibition effect of artichoke on HMG-
CoA reductase in the cholesterol biosynthesis 
pathway [19]. Nevertheless, most of the previous 
studies on artichoke focus less on enzyme 
involving in triglyceride metabolism, especially 
PAP enzyme, in details. To the best of our 
knowledge, there is no study investigating the 
effect of artichoke on PAP in 
hypercholesterolemic animals or humans. 
Therefore, the aim of this study was to determine 
the effects of dietary supplementation with 
artichoke on the liver PAP, plasma lipids, liver 
triglyceride content, plasma antioxidant, and 
malondialdehyde (MDA) levels in rats fed by 
lipogenic diet. 
 
 
Materials and methods 
Chemicals 
Phosphatidic acid (sodium salt), dithiothreitol 
(DTT), 2,4,6-tripyridyl-s-triazine (TPTZ), and 
phenylmethylsulfunyl fluoride (PMSF) were 
purchased from Sigma (Sigma Chemical Co., 
USA). Sodium tetraborate, bovine serum 
albumin, Tris–HCl, ethylenediaminetetra acetic 
acid (EDTA), ethyleneglycol-bis (beta-
aminoethyl ether)-N,N,N',N'-tetraacetic acid 
(EGTA), sucrose, 2-thiobarbituric acid (TBA), 
and ferric chloride (FeCl3.6H2O) were provided 
from Merck (Germany). All other chemicals used 
were of analytical grade.  
 
Preparation of artichoke 
The artichoke used in our study was obtained 
from Isfahan Agricultural Research Center (Iran). 
Then, the 10% artichoke pellets were made by 
mixing 10 g of dried and crushed artichoke with 
90 g of powdered standard rat pellet diet. 
 
Animals and experimental design 
Male Wistar albino rats (150-200 g) were 
maintained at approximately 22 ◦C with a 12 h 
light/12 h darkness cycle, and had free access to 
food and tap water. They were randomly divided 
into 4 diet groups (n = 6/ group) as below: 
 
Group I, normal control rats which received 
standard pellet chow. 
Group II, animal rats fed with a standard pellet 
chow supplemented with 10% artichoke.  
Groups III and IV, the rats fed with a lipogenic 
diet containing standard pellet chow 
supplemented with 0.5% cholic acid, 20% 
sunflower oil, and 2% cholesterol for two wk to 
produce hyperlipidemia. Additionally, group III 
and group IV drank water containing 3% ethanol 
[20]. In group III, after 2 weeks, 10% artichoke 
was added into lipogenic regime for 45 days, 
whereas the rats in group IV were maintained on 
lipogenic diet (hyperlipidemic control group). On 
d 60 of the experiment, fasted animals 
anesthetized with chloroform and their blood 
samples were collected in test tubes containing 
EDTA through cardiac puncture. All plasma 
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specimens were separated by low speed 
centrifugation (2000g) for 10 min and were 
stored at 80 ºC until they were analyzed. All 
animal procedures were performed with regard to 
Iranian animal ethics society and local university 
rules.  
 
Analytical procedures:  
Total cholesterol (TC), plasma TG and high 
density lipoprotein cholesterol (HDL-C) levels 
were determined by enzymatic method (Pars 
Azmun kit, Iran) with JENWAY 
spectrophotometer (model 6105, England). Low 
density lipoprotein cholesterol (LDL-C) and very 
low density lipoprotein cholesterol (VLDL-C) 
were calculated with Fridewald formula [21]. 
Liver triglyceride was extracted from liver tissue 
by Folch-altered method which invented by 
Norman [22].  
  
Preparation of rat liver homogenate:  
The liver of each rat was perfused through the 
inferior vena cava with ice-cold saline (0.9%) to 
remove blood and inorganic phosphate from it to 
assess the liver PAP activity and the liver content 
triglyceride. A portion of perfused liver was 
homogenized in 4 volumes of ice-cold buffer (pH 
7.4) containing 50 mM Tris–HCl, 0.25 M 
sucrose, 1 mM PMSF and 0.1 mM EDTA by 
homogenizer (Heidolph, Silentcrusher M model, 
Germany) at 8000 rpm at 4 ºC for 5 min [23]. 
The homogenate was centrifuged at 4500 rpm at 
4 ºC for 10 min and then, the supernatant kept for 
the enzyme assay.   
 
Determination of PAP activity:  
PAP activity was measured in the assay buffer 
(250 μl) containing 50 mM Tris–HCl (pH 7.4), 1 
mM EGTA, 1 mM DTT, 1 mM EDTA, 2 mM 
Mg Cl2, 0.35 mM phosphatidate, and appropriate 
amount of the enzyme solution. After 10 min 
incubation at 37 °C, the reaction was stopped by 
addition of 0.5 ml trichloroacetic acid (10%). 
Hence, the released Pi was measured [23]. All 
PAP activity assays were linear in relation to the 
protein concentrations and the incubation time 
used in them. The release of 1 μmole of Pi per 
min was defined as one unit (U) of PAP activity. 
Specific activity was considered as units per mg 
protein. Protein concentration was determined by 
method of Bradford [24]. 
 
Measurement of malondialdehyde:  
The plasma MDA level was determined using 
thiobarbituric acid according to the method of 
Ohkawa [25]. The plasma samples were 
incubated for 1 hour at 95°C with thiobarbituric 
acid, after the reaction of MDA with 
thiobarbituric acid, the reaction product was 
followed spectrophotometrically at 532 nm. The 
measurements were done in duplicates and the 
results were expressed in μM. MDA standards 
were prepared from 1,1,3,3-tetraethoxypropane 
(TEP). 
 
Ferric reducing/antioxidant power (FRAP) 
assay:  
The antioxidant capacity of each sample was 
measured according to the procedure described 
by Benzie and Strain [26]. In this method, the 
complex between Fe2+ and TPTZ gives a blue 
color with absorbance at 593 nm. FeSO4.7H2O 
was used as a standard of FRAP assay at a 
concentration range between 100 to 1000 μM.  
 
Table 1. The specific activity of PAP and liver 
triglyceride in experimental groups. 
Groups PAP activity 
(nmolPi/min/mg  
protein) 
Liver 
triglyceride 
(mg/g tissue) 
Group I  
( control) 
9.41 ± 0.39 3.80 ± 0.39 
Group II 8.52 ± 0.90*# 2.64 ± 0.35* 
Group III 6.46 ± 0.61* 5.16 ± 0.10*# 
Group IV 6.73 ± 0.27* 7.38 ± 0.52* 
The data were expressed as Mean ± S.D.; n = 6 in each 
group. Normal control (I); control supplemented 
with10% artichoke (II); hyperlipidemic rats treated 
with 10% artichoke (III); hyperlipidemic rats without 
treatment (IV) groups. 
 
* P < 0.05 compared with the corresponding value for 
group I (normal control animals). 
 
# P < 0.001 compared with the corresponding value for 
group IV (hyperlipidemic animals). 
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Table 2. Effect of artichoke on TC, TG, LDL-C, HDL-C, VLDL-C levels and atherogenic index in hyperlipidemic rats. 
Atherogenic index (units) Groups TC (mg/dl) TG (mg/dl) HDL-C (mg/dl) LDLC (mg/dl) VLDL-(mg/dl) 
TC/HDL-C LDL/HDL-C 
I 87.71  ±  13.61 56.98±6.22 51.67±5.39 23.52±2.07 10.50±2.43 1.70±0.16 0.47±0.13 
II 53.36  ± 7.34* 46.68±4.62 41.32±2.16* 4.94±1.82* 9.45±1.10 1.29±0.10* 0.11±0.05* 
III 79.20  ±  6.75** 49.01±6.10** 52.13±2.87 17.43±2.51** 9.80±2.34** 1.52±0.03** 0.33±0.05** 
IV 146.25  ±  29.93# 75.56±4.07# 58.41±8.72 70.67±10.81# 15.11±0.95# 2.42±0.26* 1.21±0.23* 
The data are expressed as mean ± S.D.; n = 6 in each group. Normal control (I); control supplemented with 10% 
artichoke (II); hyperlipidemic rats treated with 10% artichoke (III); hyperlipidemic rats without treatment (IV) groups. 
 
* P < 0.001 compared with the corresponding value for group I (normal control animals). 
**P < 0.001 compared with the corresponding value for group IV (lipogenic regime). 
# P < 0.001 compared with the corresponding value for groups I and II.  
 
Statistical analysis  
All data were expressed as mean ± S.D. The data 
were analyzed by SPSS software (version 11.5). 
Data were analyzed using one-way analysis of 
variance (ANOVA) followed by Tukey post hoc 
test for multiple comparison. Differences were 
considered significant at P < 0.05 level.  
 
Results 
Table 1 summarizes the effect of artichoke on the 
liver triglyceride and PAP activity in 
experimental groups. Group II showed a 
significant reduction (P < 0.05) in the liver PAP 
activity compared to group I. No significant 
change (P > 0.05) was observed in liver PAP 
activity of group IV compared to group III. Also, 
there was a noticeable reduction (P < 0.05) in 
PAP activity between groups III and IV 
compared to group I. Group IV showed a 
significant increase (P < 0.001) in the liver 
triglyceride in comparison with groups I and III. 
The liver triglyceride declined (P < 0.05) in 
groups II and III compared with groups I and IV, 
respectively. 
 
Effect of artichoke on plasma lipid levels:  
Table 2 shows the mean plasma levels of TG, TC, 
HDL-C, LDL-C, VLDL-C, and atherogenic index 
in experimental groups. The levels of plasma TG, 
TC, VLDL-C, and LDL-C in group IV 
(consuming lipogenic diet) were significantly 
increased (P < 0.05) compared to other groups. 
Additionally, the plasma HDL-C in group III had 
no significant change (P > 0.05) compared to 
group IV. In groups II and III, the plasma level of 
cholesterol significantly decreased (P < 0.001) in 
comparison with groups I and IV, respectively. 
The plasma level of TG in the rats which 
consumed standard diet supplemented with 
artichoke (group II) was lower than group I 
(control group) but it was not significant (P > 
0.05). On the other hand, the plasma level of TG 
in group III (consuming oil and cholesterol diet 
supplemented with10% artichoke) significantly 
decreased (P < 0.001) compared to group IV. In 
group II the plasma levels of HDL-C and LDL-C 
significantly decreased (P < 0.001) compared to 
group I. VLDL-C was declined in group II in 
contrast with group I (control group) but it was 
not significant (P > 0.05). VLDL-C in group III 
showed an important reduction (P < 0.001) 
compared with group IV. There was a significant 
(P < 0.001) elevation in atherogenic index 
(TC/HDL-C and LDL/ HDL-C) of group IV with 
respect to group I while, a significant reduction 
(P < 0.001) was observed in groups II and III 
compared with groups I and IV respectively.  
 
Effect of artichoke on the plasma level of 
MAD:  
Figure 1 shows that plasma MAD was 
significantly increased (P < 0.05) in group IV 
after the consumption of lipogenic diet when 
compared with other groups. On the other hand, 
in group II the consumption of artichoke led to a 
significant (P < 0.001) reduction of plasma MAD 
in comparison with group I (control). Also, in 
group III a significant (P < 0.001) reduction of 
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plasma MAD was seen as compared with group 
IV. 
Effect of artichoke on the plasma level of 
antioxidant power:  
Figure 2 shows the plasma antioxidant values in 
each experimental group. At the end of the work, 
a significant increase (P < 0.05) was found in the 
FRAP values of group II compared to the groups 
I and IV. No significant change was observed in 
plasma level antioxidant power between groups II 
and III (P > 0.05). Also, there was a noticeable 
difference (P < 0.01) between groups III and IV. 
 
 
 
Figure 1. Plasma malondialdehyde level in normal diet (I); normal diet supplemented with 10% artichoke (II); 
hyperlipidemic rats treated with 10% artichoke (III); hyperlipidemic rats without treatment (IV) groups. The data are 
expressed as mean ± S.D, n = 6 in each group.  
 
# P < 0.001 compared with the corresponding value for normal control animals.  
*P < 0.001 compared with the corresponding value for hyperlipidemic rats without treatment. 
 
 
 
Figure 2. Plasma antioxidant capacity (FRAP) in normal diet (I); normal diet supplemented with 10% artichoke (II); 
hyperlipidemic rats treated with 10% artichoke (III); hyperlipidemic rats without treatment (IV) groups. The data are 
expressed as mean ± S.D, n = 6 in each group.  
# P < 0.05 compared with the corresponding value for normal control animals. 
*P < 0.05 compared with the corresponding value for hyperlipidemic rats without treatment. 
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Discussion  
Hyperlipidemia with serum elevated 
concentrations of cholesterol and triacylglycerol 
is considered to be the cause of cardiovascular 
disease [27]. Treatment of hyperlipidemia needs 
diet control, exercise, and using lipid-lowering 
compounds such as drugs and diet [28]. Lipid-
lowering drugs such as fibrates and bile acid 
sequestrants were used for many years. 
Nevertheless, the side effects of drugs led to 
synthesis new oral antihyperlipidemic drugs such 
as statins (HMG CoA reductase inhibitors). 
 
Although the side effect of statins is relatively 
low but, they can cause rhabdomyolysis condition 
[29]. Therefore, the research for natural 
compounds with lipid-lowering properties and 
with less or no adverse effects, especially 
medicinal plants, is warranted. These plants 
contain biological active substances including 
antioxidant, hypoglycemic, and hypolipidemic 
compounds. Unfortunately, there is less 
information about enzymatic or lipid-lowering 
mechanisms for many of these medicinal plants, 
especially their effects on PAP enzyme. In this 
respect, we reported the effect of garlic on the 
liver PAP activity in normal and hyperlipidemic 
rats [30]. The supplementation of garlic, as a 
medicinal plant, led to reducing liver PAP 
enzyme and liver TG. In this study, our data have 
shown that artichoke supplementation in 
hyperlipidemic rats lead to highly effective in 
reducing plasma cholesterol and LDL levels as 
compared to the high cholesterol and control diet 
groups (Table 2). Also, artichoke caused 
significant decreases in TG and the ratio of 
cholesterol to HDL cholesterol in plasma of rats 
fed by lipemic diet. Lipid lowering effects of 
artichoke has been reported by other investigators 
[6, 8]. Studies on cultured hepatocytes suggested 
that artichoke inhibits the incorporation of 14C-
labelled acetate into the non-saponifiable lipid 
fraction and thus reduces the cholesterol 
biosynthesis. Luteolin, a flavonoid constituent of 
artichoke, was found to play a major role in the 
inhibition of cholesterol biosynthesis and 
reduction of serum cholesterol [19]. Moreover, 
chlorogenic acid is another bioactive component 
of artichoke that reported as lipid-lowering agent 
in the artichoke [7, 31].  Nevertheless, the 
published works do not assess the effect of 
artichoke on PAP activity and liver TG in 
hyperlipidemic rats. In our study the artichoke 
supplementation results in higher reduction of 
PAP activity (Tables 1) and liver TG in group II 
than group I (control). Although, the reduction of 
the plasma TG in group II was not significant, it 
was accompanied with a decline in the liver PAP 
activity in this group (Tables 1 and 2). On the 
other hand, in animals fed by lipemic regime 
(groups III and IV) PAP activity decreased with 
respect to control group whereas, their liver TG 
concentration increased in this study (Table 1). It 
has been reported that excessive intake of fatty 
acids results in accumulation of TG in many 
tissues, especially in fat tissue and non-adipose 
tissues such as liver [32]. In addition, it was 
shown that fatty acid esters lead to the 
inactivation of PAP. Fatty acids and their acyl-
CoA esters regulate PAP by a negative allosteric 
interaction. The formation of PAP fatty acid (or 
acyl-CoA esters) complex results in the 
inactivation of PAP [33]. Therefore, the reduction 
of PAP activity in this study in groups fed with 
high lipid regime (groups III and IV) is due to the 
accumulation of TG, fatty acids or acyl-CoA 
esters in the liver (Table 1). Nevertheless, the 
reduced activity of PAP in groups fed with high 
lipid regime (Groups II and III) can probably act 
as a defense mechanism of liver for reducing the 
production of endogenous liver TG. Thus, serum 
and liver TG will decline and likely, reduce the 
risk of liver damage especially fatty liver and 
cirrhosis. Besides, in our study liver fat 
concentration significantly increased in animal 
groups fed by lipogenic regime (Groups III and 
IV) compared to the group I (normal control). 
The elevated liver fat in group III was 
significantly reduced as opposed group IV (Table 
1) through the supplementation with artichoke. 
Therefore, the artichoke leaves can be able to 
reduce the liver content of TG by diminishing 
PAP activity. Overall, artichoke can be useful in 
lowering and the treatment of fatty liver in 
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hyperlipidemic regime. Moreover, the artichoke 
supplementation with lipogenic regime led to 
reduction of plasma LDL-cholesterol and 
atherogenic index. These results indicate that 
artichoke can be applicable for reducing the 
coronary heart diseases in hyperlipidemic 
conditions.  
 
In this study, we did not evaluate the effects of 
artichoke on the other enzymes involving in the 
lipid metabolism, especially glucose-6-phosphate 
dehydrogenase (G6PDH) and malic enzyme. 
These enzymes generate NADPH employed for 
fatty acid and cholesterol syntheses. We suggest 
that future studies focus on other possible 
mechanisms of the triglyceride-lowering action of 
the artichoke or the bioactive components of 
artichoke on the mentioned enzymes. 
 
Oxidative stress of plasma lipoproteins, 
erythrocytes and several tissues such as liver, 
heart and aorta have been reported in 
experimental animals fed on high cholesterol diet 
[6, 34, 35]. Increased oxidative stress parameters 
have been detected in hypercholesterolemic 
individuals [36]. The level of MDA is considered 
as a biomarker of lipid peroxidation [37].  In the 
present study, artichoke supplementation caused 
significant decreases in plasma lipid peroxidation 
together with elevation of plasma antioxidant 
power (Figs. 1and 2). In this respect, there are 
published reports concordant with our results [6, 
38]. Artichoke is known to have antioxidant 
effect. Previous studies have reported that the 
antioxidant potential of artichoke is dependent on 
radical scavenging by its constituents such as 
cynarin, chlorogenic acid and flavonoids such as 
caffeoylquinic acids [39, 40]. Both caffeoylquinic 
acids and flavonoids present in artichoke are 
considered to be responsible for its anti-
atherogenic actions through their antioxidant 
capacity [11].The antioxidant barriers of the 
artichoke extract’s constituents rely on the 
inhibition of ROS generation, ROS 
neutralization, or the induction of endogenous 
antioxidants [10, 40, 41]. Therefore, on the basis 
of our results, artichoke can probably play an 
anti-atherogenic role by lowering lipids oxidation 
in hyperlipidemic diets. 
 
Conclusion 
Our findings indicate that artichoke can be useful 
to decrease PAP activity, liver triglyceride, 
oxidative stress, plasma cholesterol, and 
triglyceride levels in hyperlipidemic rats.  Also, 
artichoke has beneficial effects in the control of 
fatty liver, plasma lipid abnormalities, 
hyperlipidemia, and oxidative stress in 
hyperlipidemic diet conditions.  
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